SVS Medical LLC announces completion of new $1.75 million venture financing round for Eulysis Inc. & BioFaran Laboratories S.A.

The investment deal was formalized recently and is pending completion to launch the world-leading and acclaimed healthcare technologies.
HUDSON, Mass. - July 29, 2016 - PRLog -- Prof. Dr. S Tsakas II agreed Heads of Terms and finalized all pre-funding activities on the investment earlier today, Friday, July 29, 2016. According to the terms of the investment agreement, the investor who chose to remain anonymous will remain a shadow director of the business while allowing Prof. Dr. S Tsakas II (also known as Ross) to manage the funds through STFIH Group, a wealth manager that has been account handling SVS Medical LLC since its inception. In the new agreement, there still remains to be confirmation as to the specifics surrounding the funding and which of the two subsidiary companies of SVS Medical LLC will be funded.

Prof. Dr. S Tsakas stated, "We are pleased to see that the financing round was completed less than a week after its formal commencement. Traction and interest in both subsidiaries is key to our future momentum in releasing these technologies to the market." Choosing to avoid a direct response regarding the further details of the investment agreement, Ross replied, "It is still in the works. I figure we can devise a short term strategy so that the funds can accomplish short term goals in both initiatives. With a small round of financing, BioFaran Laboratories can launch a pilot study with the current global manufacturer based in Europe and approach the US market. With an equally small round of financing, we can also take the Eulysis SVS technology to market launch. So I anticipate finding a balance that achieves maximum return on investment for all parties."

With the recent funding round completed, it appears as though both of the opportunities available through SVS Medical LLC have temporarily been paused. "We want to manage funds appropriately and ensure that our investors are sequentially happy. Firstly, we have a commitment to delivering upon the current investor's plans for short and long term wealth management," was the response to the question about seeking further investors/investment.

In the near future, the company also plans to establish a regional manufacturing facility in the Northeast to provide a base of operations through which the SVS for cosmetic and pharmaceutical applications will be manufactured up to FDA standards. "Choosing this approach we are able to state with confidence that the products have been manufactured up to the recent ISO and relevant quality standards applicable to each industry. We wish to retain a strong position as a supplier of high quality yet affordable packaging solutions," Ross said.

For more information, please visit www.svsmedical.com.

Contact
A Welsh
***@gmail.com
End
Source: » Follow
Email:***@gmail.com
Tags:Venture Investment, Venture Capital, Biotechnology
Industry:Business
Location:Hudson - Massachusetts - United States
Subject:Projects
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share